Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?

Research output: Contribution to journalArticle

19 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1939-1940
Number of pages2
JournalLeukemia
Volume27
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Piperazines
Benzamides
Pyrimidines
Arterial Occlusive Diseases
Peripheral Arterial Disease
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antineoplastic Agents
Atherosclerosis
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Nilotinib treatment-associated accelerated atherosclerosis : When is the risk justified? / Tefferi, Ayalew.

In: Leukemia, Vol. 27, No. 9, 09.2013, p. 1939-1940.

Research output: Contribution to journalArticle

@article{44d5b0cba8a84609b1851aca19edccbc,
title = "Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?",
author = "Ayalew Tefferi",
year = "2013",
month = "9",
doi = "10.1038/leu.2013.112",
language = "English (US)",
volume = "27",
pages = "1939--1940",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Nilotinib treatment-associated accelerated atherosclerosis

T2 - When is the risk justified?

AU - Tefferi, Ayalew

PY - 2013/9

Y1 - 2013/9

UR - http://www.scopus.com/inward/record.url?scp=84883741352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883741352&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.112

DO - 10.1038/leu.2013.112

M3 - Article

C2 - 23604230

AN - SCOPUS:84883741352

VL - 27

SP - 1939

EP - 1940

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 9

ER -